Absci (ABSI) Expected to Announce Earnings on Tuesday

Key Points

• Absci is set to announce its Q2 2025 earnings on August 13, expecting to report a loss of ($0.19) per share and revenue of $1.39 million.
• Recent analysts' ratings for Absci reflect mixed sentiments, with price targets ranging from $6.40 to $9.00 and a consensus rating of "Moderate Buy".
• Insider Andreas Busch purchased 50,000 shares, increasing his ownership in Absci by 18.03%, indicating confidence in the company's potential.

Absci (NASDAQ:ABSI - Get Free Report) is projected to announce its Q2 2025 earnings results after the market closes on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $1.39 million for the quarter.

Absci (NASDAQ:ABSI - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.02. The business had revenue of $1.18 million during the quarter, compared to analysts' expectations of $1.07 million. Absci had a negative net margin of 2,232.13% and a negative return on equity of 53.69%. On average, analysts expect Absci to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Absci Price Performance

ABSI traded down $0.08 during trading on Friday, hitting $2.84. 3,240,773 shares of the stock traded hands, compared to its average volume of 6,638,382. The firm has a market capitalization of $362.27 million, a P/E ratio of -3.09 and a beta of 2.02. The firm has a 50-day moving average of $2.87 and a 200 day moving average of $3.19. Absci has a 12-month low of $2.01 and a 12-month high of $6.33.

Insider Activity at Absci

In other Absci news, insider Andreas Busch purchased 50,000 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was bought at an average cost of $3.04 per share, with a total value of $152,000.00. Following the transaction, the insider directly owned 327,264 shares in the company, valued at approximately $994,882.56. The trade was a 18.03% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 10.49% of the company's stock.

Institutional Investors Weigh In On Absci

Several hedge funds have recently bought and sold shares of the business. Creative Planning boosted its stake in Absci by 145.4% during the second quarter. Creative Planning now owns 46,882 shares of the company's stock worth $120,000 after acquiring an additional 27,775 shares in the last quarter. AQR Capital Management LLC boosted its stake in Absci by 279.4% during the first quarter. AQR Capital Management LLC now owns 55,538 shares of the company's stock worth $139,000 after acquiring an additional 40,901 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Absci by 17.5% during the first quarter. Goldman Sachs Group Inc. now owns 314,858 shares of the company's stock worth $790,000 after acquiring an additional 46,975 shares in the last quarter. Woodline Partners LP boosted its stake in Absci by 32.9% during the first quarter. Woodline Partners LP now owns 1,391,245 shares of the company's stock worth $3,492,000 after acquiring an additional 344,270 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Absci by 22.5% during the second quarter. Geode Capital Management LLC now owns 2,445,450 shares of the company's stock worth $6,286,000 after acquiring an additional 448,984 shares in the last quarter. Institutional investors own 52.05% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on ABSI shares. Needham & Company LLC reissued a "buy" rating and set a $9.00 price target on shares of Absci in a research report on Wednesday, May 14th. KeyCorp raised their target price on shares of Absci from $5.00 to $9.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 16th. Morgan Stanley dropped their target price on shares of Absci from $7.00 to $6.40 and set an "overweight" rating for the company in a research report on Monday, July 28th. Finally, Wall Street Zen raised shares of Absci from a "sell" rating to a "hold" rating in a research report on Saturday, August 2nd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.28.

Absci Company Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.